DNL Diurnal Group Plc

TIDMDNL

RNS Number : 1127X

Diurnal Group PLC

21 November 2017

21 November 2017

Diurnal Group plc

("Diurnal" or the "Company")

Results of Annual General Meeting

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed.

 
 For further information, please visit www.diurnal.co.uk 
  or contact: 
 
                                           +44 (0)20 3727 
 Diurnal Group plc                          1000 
 Martin Whitaker, Chief Executive 
  Officer 
 Richard Bungay, Chief Financial 
  Officer 
 
 Numis Securities Ltd (Nominated           +44 (0)20 7260 
  Adviser)                                  1000 
 Nominated Adviser: Michael Meade, 
  Paul Gillam, Freddie Barnfield 
 Corporate Broking: James Black 
 
 Panmure Gordon (UK) Limited (Joint        +44 (0) 20 7886 
  Broker)                                   2500 
 Corporate Finance: Freddy Crossley 
  / Duncan Monteith 
 Corporate Broking: Tom Salvesen 
 
                                           +44 (0)20 3727 
 FTI Consulting                             1000 
 Simon Conway 
 Victoria Foster Mitchell 
 

Notes to Editors

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGBBBBTMBITBFR

(END) Dow Jones Newswires

November 21, 2017 07:00 ET (12:00 GMT)

Diurnal (LSE:DNL)
Historical Stock Chart
From Mar 2024 to Apr 2024

Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2023 to Apr 2024